Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (86)	2/15/2000 10:04:00 PM
From: Dave K	Respond to of 1833

Rick, I could not understand why you were all talking about "portable patents". Thanks for clearing that up ! Finally explains why Solvay remained in the OSIP deal. Lots of information to digest (& I'm slow). OT: The upcoming $100m IPO mentioned earlier is Genomic Solutions....no connection whatsoever....DNA/biochip stuff. Their tech appears to sell. Probably will have a huge IPO. I can access Axiom site again. Note blackout since April 99. I feel like I'm thrashing a dead horse. This is what I was looking for... all sounds like good stuff. GENE, AXIOM & CADUS should bundle their instruments together into one big discovery tool package -g- Snipped from below... "This accelerated sample throughput in conjunction with the multi-parametric capabilities of flow cytometry could provide a single system capability to conduct >>> tens of thousands of multiplexed assay per day"<<< ============= Axiom Biotechnologies Licenses High-Speed Flow Cytometry Fluidics Handling Technology From University of New Mexico SAN DIEGO, CA, Wednesday, April 14, 1999 - Axiom Biotechnologies, Inc. today announced that the Company has entered into an exclusive, long-term license agreement with the Science & Technology Corporation @ UNM for a novel fluidics technology, Plug-Flow Cytometry (PFC), that dramatically accelerates the sampling rates and throughput capabilities of flow cytometry. Axiom will apply this technology in conjunction with its own HT-PS© fluidics technology to evolve flow cytometry into a high-speed, high information content drug discovery tool. "Plug-flow cytometry offers an elegant means of accelerating the delivery of samples to a flow cytometer from microtiter plates or other sampling vessels," said Pandi Veerapandian, Axiom's Chairman and President. "The addition of PFC to our technology portfolio will broaden the application of our HT-PS© technology and enable us to incorporate the well validated aspects of flow cytometry into a drug discovery platform capable of performing high-speed, multi-parameter measurements on dynamic or static endpoint cellular assays," Currently, flow cytometers are not automated systems and provide throughput levels incompatible with the needs of drug discovery, delivering approximately one sample or less per minute to the flow cytometer. The PFC technology designed by Larry Sklar, Ph.D. and his research team at University of New Mexico facilitates dramatically enhanced delivery rates for samples, such that thousands of samples can be analyzed per day on a single system. This accelerated sample throughput in conjunction with the multi-parametric capabilities of flow cytometry could provide a single system capability to conduct tens of thousands of multiplexed assay per day. This would revolutionize the application of flow cytometry into a high-speed information-rich lead profiling and screening technology compatible with the demands of drug discovery. Axiom and The University of New Mexico will be conducting joint research to demonstrate the capabilities of and further develop this new technology. Science & Technology Corporation @ UNM (STC), located in Albuquerque, New Mexico, is an independent, non-profit organization formed by the University of New Mexico for the purpose of commercializing technology created at UNM. STC maintains a portfolio of intellectual property related to such areas as optoelectronics and lasers, lithography, semiconductor fabrication and electronic materials, computer technologies and algorithms, circuit design and signal processing, materials, chemistry and chemical engineering, environmental and waste management technologies, mechanical devices, medical diagnostics, medical devices, drugs and therapeutics. Axiom Biotechnologies is a privately-held biotechnology company focused on improving the efficiency of drug discovery by accelerating the process of evolving screening 'hits' to pre-clinical leads by applying an array of proprietary 'hits'-to-leads technologies and assays. The company's patented flagship technology, the High Throughput Pharmacology System (HT-PS©), combines proprietary natural cell-based assays, high throughput automated instrumentation and novel pharmacoinformatics and biomining tools to assess and prioritize potential lead compounds based on their functional pharmacological properties. Through collaborations with major pharmaceutical companies, Axiom is committed to becoming the pharmaceutical industry's partner of choice in high throughput pharmacology.